Medicine and Dentistry
Acute Myeloid Leukemia
96%
Leukemia
34%
Ex Vivo
32%
Leukemia Cell
31%
Venetoclax
30%
Neoplasm
27%
Chronic Myelogenous Leukemia
26%
Disease
26%
Chronic Neutrophilic Leukemia
24%
Targeted Therapy
24%
Drug Response
20%
Atypical Chronic Myeloid Leukemia
19%
Receptor
19%
Malignant Neoplasm
19%
Tyrosine-Kinase Inhibitor
19%
Phosphotransferase Inhibitor
18%
Drug Sensitivity
18%
Protein Tyrosine Kinase
15%
Phosphotransferase
14%
Chronic Myelogenous Leukemia
13%
Acute Lymphoblastic Leukemia
13%
Myeloproliferative Neoplasm
13%
Dasatinib
12%
In Vitro
12%
Functional Genomics
11%
Signal Transduction
11%
Drug Resistance
11%
Hematologic Malignancy
10%
Clear Cell Renal Cell Carcinoma
9%
Rhabdomyosarcoma
9%
Programmed Cell Death
9%
Fibroblast Growth Factor 2
9%
Colony Stimulating Factor
8%
Mitogen-Activated Protein Kinase
8%
RNA Interference
8%
Ponatinib
8%
Clinical Trial
7%
Biological Marker
7%
T Cell
7%
Ruxolitinib
7%
Cytokine
6%
Xenograft
6%
Risk Stratification
6%
Quizartinib
6%
B-Cell Chronic Lymphocytic Leukemia
6%
Gene Expression
6%
Mononuclear Phagocyte
6%
Antineoplastic Activity
6%
Myeloproliferative Disorder
6%
Proteomics
6%
Biochemistry, Genetics and Molecular Biology
Myeloid
100%
Kinase
43%
Phosphotransferase
42%
Eicosanoid Receptor
28%
Receptor Tyrosine Kinase
23%
Proteomics
19%
Proteogenomics
19%
Dasatinib
17%
Genetics
17%
Drug Sensitivity
16%
Drug Response
16%
Small Molecule
14%
Tyrosine Kinase
14%
Tyrosine Kinase Inhibitor
13%
Cytokine
11%
Imatinib
10%
Functional Genomics
10%
Tyrosine
10%
Allele
9%
Drug Resistance
9%
Mouse
9%
Cancer Cell
9%
Tumor Progression
8%
Somatic Mutation
8%
P53
8%
RNA Interference
8%
Dimerization
8%
Point Mutation
7%
B Cell
7%
Hematopoiesis
7%
Kinome
7%
Monocyte
7%
Signal Transduction
7%
Antineoplastic Activity
6%
Nilotinib
6%
Replication Timing
6%
BCL6
6%
Ubiquitin
6%
Mononuclear Phagocyte
6%
Colony-Stimulating Factor
6%
Epidermal Growth Factor Receptor
6%
Mitogen-Activated Protein Kinase
6%
Colony Formation
5%
Epigenetics
5%
Survivin
5%
Phosphoproteomics
5%
Basic Fibroblast Growth Factor
5%
Missense Mutation
5%
Cell Survival
5%
IC50
5%
Keyphrases
Acute Myeloid Leukemia
64%
Venetoclax
21%
Leukemia
17%
Targeted Therapy
17%
FMS-like Tyrosine Kinase 3 (FLT3)
16%
Bcl-2 Inhibitor
13%
Leukemia Patients
13%
Kinase Inhibitor
12%
Dasatinib
12%
BCR-ABL
12%
Drug Resistance
11%
Hematological Malignancies
10%
Chronic Myeloid Leukemia
10%
Functional Genomics
9%
Therapeutic Target
9%
Inhibitor Screening
9%
Proteogenomics
9%
Chronic Neutrophilic Leukemia
9%
Drug Sensitivity
9%
Small Molecule Inhibitors
9%
Functional Screening
9%
BCR-ABL Inhibitors
8%
In Cancer
8%
Atypical Chronic Myeloid Leukemia
7%
Myeloproliferative Neoplasms
7%
Ponatinib
7%
CSF3R
7%
Acquired Resistance
7%
Myeloid Cell leukemia-1 (Mcl-1)
6%
AP24534
6%
RAS-MAPK Pathway
6%
Leukemia Microenvironment
6%
Kinome
6%
B Cell Receptor
6%
Colony-stimulating Factor 3 Receptor
6%
Tyrosine Kinase Inhibitor
5%
FLT3 mutation
5%
Hematopoietic Stem Cells
5%
Apoptosis
5%
Acute Lymphoblastic Leukemia
5%
Drug Response
5%
Asthma
5%
Therapeutic Strategies
5%
Truncating mutation
5%